CoverageForm 410-K10-Q8-K13D13G13F

ISO · Isoplexis Corp - Financials

Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.

Income Statement

Line itemFY 2022FY 2021
Revenue$16.76M$10.39M
Cost of Revenue--
Gross Profit($925.0K)$5.41M
R&D$23.50M$11.16M
SG&A$42.68M$8.02M
Total Operating Expenses$100.31M$32.69M
D&A$3.53M$879.0K
Operating Income($101.23M)($27.28M)
Interest Expense--
Income Tax--
Net Income($106.00M)($23.26M)
EPS - Basic($2.70)($14.06)
EPS - Diluted($2.70)($14.06)

Balance Sheet

Line itemFY 2022FY 2021
Cash & Equivalents$37.47M$126.57M
Accounts Receivable$4.50M$4.10M
Inventory$27.52M$24.30M
Accounts Payable$2.78M$4.84M
Current Assets$71.86M$158.44M
Total Assets$109.07M$187.47M
Current Liabilities$17.71M$13.58M
Long-term Debt$46.35M$31.65M
Total Liabilities$67.80M$45.23M
Stockholders' Equity$41.27M$142.25M
Retained Earnings($239.97M)($133.97M)

Cash Flow

Line itemFY 2022FY 2021
Operating Cash Flow($96.64M)($22.43M)
Investing Cash Flow($7.82M)($2.29M)
Financing Cash Flow$15.33M$104.00M
CapEx$7.36M$1.44M
Free Cash Flow($104.00M)($23.88M)

Ratios

MetricFY 2022FY 2021
Profitability
Gross margin-5.5%52.1%
Operating margin-604.0%-262.6%
EBITDA margin-582.9%-254.2%
Net margin-632.4%-224.0%
Free cash flow margin-620.5%-229.9%
FCF / Net income0.981.03
R&D / Revenue140.2%107.4%
SG&A / Revenue254.6%77.2%
Effective tax rate--
Return on assets-97.2%-12.4%
Return on equity-256.9%-16.4%
Return on invested capital--
Liquidity
Current ratio4.0611.67
Quick ratio2.509.88
Cash ratio2.129.32
Leverage
Debt / Equity1.120.22
Debt / Assets0.430.17
Debt / EBITDA--
Interest coverage--
Equity multiplier2.641.32
Liabilities / Assets0.620.24
Efficiency
Asset turnover0.150.06
Inventory turnover--
Days sales outstanding98d144d
Days inventory outstanding--
Days payable outstanding--
Cash conversion cycle--
Valuation
P / E--
P / B--
P / S--
EV / EBITDA--
Growth
Revenue growth (YoY)61.4%-
Revenue CAGR (3y)--
Revenue CAGR (5y)--
Gross profit growth (YoY)--
Operating income growth (YoY)-271.1%-
Net income growth (YoY)-355.6%-
EPS growth (YoY)80.8%-
EPS CAGR (3y)--
EPS CAGR (5y)--
FCF growth (YoY)-335.6%-
FCF CAGR (5y)--
Book value growth (YoY)-71.0%-

Sales by segment

From XBRL dimensional facts in the 10-K period ending 2021-12-31.

Product / service

$34.52M total
Product$16.20M · 46.9%
Product Instruments$11.42M · 33.1%
Product Consumables$4.78M · 13.9%
Service$1.06M · 3.1%
Service Extended Service Warranty$681.0K · 2.0%
Service Other$376.0K · 1.1%

Geographic

$17.26M total
Americas$12.80M · 74.2%
Europe$2.29M · 13.3%
CN$1.31M · 7.6%
Asia Pacific$860.0K · 5.0%

Stability scores

Altman Z′

FY 2022 · bankruptcy risk

-3.98
Distress

Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.

Piotroski F-score

FY 2022 · 9-point quality

2/9
Weak
  • Net income positive
  • Operating cash flow positive
  • ROA improved YoY
  • Cash flow > net income
  • Long-term debt decreased
  • Current ratio improved
  • No share dilution
  • Gross margin improved
  • Asset turnover improved

Peer comparison

Same SIC group: Laboratory Analytical Instruments

CompanyRevenue (last FY)Net marginROE
AVTR$6.55B-8.1%-9.5%
QTRX$138.90M-77.1%-36.2%
ILMN$4.34B19.6%31.2%
A---
CTKB$201.49M-33.0%-19.5%

Comparing IsoPlexis Corp against the 5 most active filers in the same SIC group.